PTG 670
Latest Information Update: 26 Apr 2023
At a glance
- Originator Praetego
- Class Antidementias; Small molecules
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Dementia
Most Recent Events
- 18 Apr 2023 Praetego has a pending patent application for inhibitors of advanced glycation end products in USA, as of April 2023
- 11 Apr 2023 Early research in Alzheimer's disease in USA (unspecified route) (Praetego pipeline, April 2023)
- 11 Apr 2023 Early research in Dementia in USA (unspecified route) (Praetego pipeline, April 2023)